Home > Boards > US Listed > Medical - Drugs > Allena Pharmaceuticals Inc (ALNA)

Here are some key dates

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Cosa Member Profile
 
Followed By 7
Posts 972
Boards Moderated 1
Alias Born 07/27/17
160x600 placeholder
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/12/2021 4:03:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/8/2021 2:51:56 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/8/2021 2:14:13 PM
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire Inc. - 4/8/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/7/2021 9:33:37 AM
Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors GlobeNewswire Inc. - 4/7/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/30/2021 8:18:41 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/30/2021 6:07:02 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/11/2021 7:39:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/11/2021 7:27:16 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/11/2021 7:17:41 AM
Allena Pharmaceuticals EPS misses by $0.05 Seeking Alpha - 3/9/2021 7:35:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/9/2021 7:01:21 AM
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire Inc. - 3/9/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/5/2021 4:05:46 PM
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March GlobeNewswire Inc. - 2/24/2021 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 5:18:40 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/8/2021 10:16:19 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 2/2/2021 6:20:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2021 6:20:08 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/2/2021 4:16:56 PM
Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial Officer GlobeNewswire Inc. - 2/2/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/28/2021 5:16:59 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 1/13/2021 9:03:37 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/6/2021 1:02:39 PM
Cosa   Friday, 09/18/20 05:22:41 PM
Re: None
Post # of 57 
Here are some key dates

Reloxaliase: Reloxaliase is a first-in-class, non-absorbed, orally administered enzyme for the treatment of severe hyperoxaluria. Allena is currently evaluating reloxaliase for patients with enteric hyperoxaluria (EH) in URIROX-2, the second pivotal Phase 3 clinical trial in its URIROX program. Allena is actively expanding to new sites and new geographies in its ongoing URIROX-2 clinical trial. The Company continues to expect the interim analysis in the first quarter of 2022 and to announce topline data supporting a potential Biologics License Application (BLA) submission in the third quarter of 2022.

Allena continues to engage with the U.S. Food and Drug Administration (FDA) to explore potential expedited registration paths for reloxaliase in patients with EH and advanced chronic kidney disease (CKD).

ALLN-346: ALLN-346 is a first-in-class, orally administered, novel urate degrading enzyme that has been designed for activity and stability in the gastrointestinal tract for the treatment of hyperuricemia in patients with gout in the setting of advanced CKD. In July 2020, Allena initiated a Phase 1 clinical trial of ALLN-346. Initial data is expected in the fourth quarter of 2020.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences